Company intelligence / Profile preview

GlyProVac

Ownership: Private
Development stage: Preclinical

Overview

GlyProVac is developing GPV02, a maternal vaccine targeting E. coli for prevention of neonatal sepsis. The company received CARB-X funding of $467,000 in February 2024 to support this development.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Vaccines
Industry: Biotech

Drug pipeline

1 asset

GPV02

Preclinical

Partnerships

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

Beyond the preview

Go deeper on GlyProVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlyProVac.

Explore the full profile